Abstract
Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.
| Original language | English (US) |
|---|---|
| Pages | 41-44 |
| Number of pages | 4 |
| Volume | 41 |
| No | 8 |
| Specialist publication | U.S. Pharmacist |
| State | Published - Aug 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacy
- Pharmacology
- Pharmaceutical Science
Cite this
Gonorrhea : Treatment and management considerations for the male patient. / Dalke, Brian; Ivers, Timothy; O’Brien, Karen K.; Castillo, Shana; Hoie, Eric; Begley, Kimberley J.
In: U.S. Pharmacist, Vol. 41, No. 8, 01.08.2016, p. 41-44.Research output: Contribution to specialist publication › Article
}
TY - GEN
T1 - Gonorrhea
T2 - Treatment and management considerations for the male patient
AU - Dalke, Brian
AU - Ivers, Timothy
AU - O’Brien, Karen K.
AU - Castillo, Shana
AU - Hoie, Eric
AU - Begley, Kimberley J.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.
AB - Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.
UR - http://www.scopus.com/inward/record.url?scp=84983070756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983070756&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84983070756
VL - 41
SP - 41
EP - 44
JO - U.S. Pharmacist
JF - U.S. Pharmacist
SN - 0148-4818
ER -